| Literature DB >> 26083627 |
Christina Li-Ping Thio1, Rohana Yusof2, Ali Ashrafzadeh3, Syareena Bahari4, Puteri Shafinaz Abdul-Rahman5, Saiful Anuar Karsani6.
Abstract
The Chikungunya virus (CHIKV) is an arthropod borne virus. In the last 50 years, it has been the cause of numerous outbreaks in tropical and temperate regions, worldwide. There is limited understanding regarding the underlying molecular mechanisms involved in CHIKV replication and how the virus interacts with its host. In the present study, comparative proteomics was used to identify secreted host proteins that changed in abundance in response to early CHIKV infection. Two-dimensional gel electrophoresis was used to analyse and compare the secretome profiles of WRL-68 cells infected with CHIKV against mock control WRL-68 cells. The analysis identified 25 regulated proteins in CHIKV infected cells. STRING network analysis was then used to predict biological processes that may be affected by these proteins. The processes predicted to be affected include signal transduction, cellular component and extracellular matrix (ECM) organization, regulation of cytokine stimulus and immune response. These results provide an initial view of CHIKV may affect the secretome of infected cells during early infection. The results presented here will compliment earlier results from the study of late host response. However, functional characterization will be necessary to further enhance our understanding of the roles played by these proteins in the early stages of CHIKV infection in humans.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26083627 PMCID: PMC4470940 DOI: 10.1371/journal.pone.0129033
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Relative cell viability (A) and percentage of cell lysis (B) of WRL-68 cells grown in DMEM growth medium (10% FBS) and serum-free medium for 24 hours.
A: Cell viability was normalised to 100%, and the relative viability of serum-starved cells was determined. At 24 hours incubation, the absence of serum did not significantly reduce cell viability as percentage of viability was above 98%. Data presented are representative of three independent experiments and the error bars represent standard deviation. B: Percentage of cell lysis for digitonin-lysed cells (positive control) was normalised to 100%. The absence of serum in the culture medium was found to have no significant effect on cellular disruption. Similarly, WRL-68 cells infected with CHIKV at the MOI of 5.0 showed similar percentage as the mock control cells. Data presented are representative of three independent experiments and the error bars represent standard deviation.
Fig 2Representative secretome map of WRL-68 cells.
A total of 40μg of mock control and CHIKV-infected WRL-68 secretome were resolved on 13 cm linear Immobiline DryStrip, pH 3–10 in the first dimension and 12.5% SDS-PAGE gel in the second dimension. The silver stained gels were analysed using ImageMaster gel analysis software. A total of 34 protein spots were determined to be differentially expressed, nine of which were up-regulated (circled in orange) whereas 25 were down-regulated (circled in blue). Boxed areas (I, II, III and IV) show the location of the expanded images illustrated in .
Fig 3Expanded views showing the location of differentially expressed protein spots on the mock control and CHIKV-infected WRL-68 secretome gels.
Expanded view of five sections—I, II, III and IV, showing differentially expressed proteins between A: mock control and B: CHIKV-infected 2DE gels. Spots 1 to 9 refer to up-regulated protein spots, whereas DS10 to DS34 refer to down-regulated protein spots. Five biological replicates per group (n = 5) were used in the analysis.
Proteins with different abundance in the secretome of CHIKV infected cells identified by MALDI-TOF/TOF MS.
| Spot no. | Protein ID | Abbreviation | Swissprot accession number | MOWSE score (% coverage) | Experimental pI/MW (theoretical pI/MW) | Mean spot volume: MOCK-control Mean ± SD | Mean spot volume: CHIKV-infected Mean ± SD | Fold-change ( | Fold-change ( | Peptides matched |
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| * |
|
|
|
|
|
|
|
|
|
|
|
| Cathepsin L1 (EC 3.4.22.15) | CTSL1 | P07711 | 109 (5) | 5.31/37.5 (6.5/39.8) | 0.1904 ± 0.048 | 0.1072 ± 0.027 | -1.78 (0.010) | 2 | |
|
| Cathepsin L1 (EC 3.4.22.15) | CTSL1 | P07711 | 109 (5) | 5.31/37.5 (6.6/39.8) | 0.3237 ± 0.067 | 0.1280 ± 0.051 | -2.53 (0.001) | 2 | |
| * |
|
|
|
|
|
|
|
|
|
|
|
| β-2 microglobulin | B2M | P61769 | 68 (8) | 6.06/13.7 (6.8/7.3) | 0.9748 ± 0.157 | 0.5797 ± 0.125 | -1.68 (0.002) | 1 | |
|
| Cystatin-3 | CST3 | P01034 | 179 (47) | 9.00/15.8 (8.5/9.5) | 0.1393 ± 0.025 | 0.0512 ± 0.013 | -2.72 (0.000) | 14 | |
|
| ||||||||||
|
| Glutamate receptor subunit 3A precursor | GRIN3A | Q8TCU5 | 44 (11) | 7.81/125.5 (6.0/42.2) | 0.0308 ± 0.013 | 0.0941 ± 0.046 | 3.05 (0.014) | 18 | |
|
| Ran-specific GTPase-activating protein | RANBP1 | P43487 | 102 (19) | 5.19/23.3 (5.3/23.0) | 0.0243 ± 0.003 | 0.0438 ± 0.012 | 1.80 (0.011) | 9 | |
|
| GTP-binding nuclear protein Ran | RAN | P62826 | 227 (51) | 7.01/24.4 (7.7/22.1) | 0.0594 ± 0.010 | 0.2185 ± 0.036 | 3.68 (0.000) | 19 | |
|
| Vesicular integral-membrane protein VIP36 precursor | LMAN2 | Q12907 | 473 (44) | 6.46/40.2 (5.5/33.7) | 0.0307± 0.018 | 0.0136 ± 0.003 | -2.25 (0.050) | 23 | |
|
| Tubulointerstitial nephritis antigen-like precursor | TINAGL1 | Q9GZM7 | 85 (16) | 6.54/52.4 (7.0/55.4) | 0.0475± 0.009 | 0.0170 ± 0.010 | -2.79 (0.001) | 11 | |
|
| ||||||||||
|
| Collagen alpha-1(V) chain precursor | COL5A1 | P20908 | 199 (9) | 4.94/183.4 (4.2/34.8) | 0.1119 ± 0.036 | 0.0356 ± 0.013 | -3.14 (0.002) | 25 | |
|
| Cadherin-2 precursor | CDH2 | P19022 | 405 (11) | 4.64/99.7 (5.9/10.4) | 0.2778 ± 0.060 | 0.0935 ±0.042 | -2.97 (0.001) | 18 | |
|
| ||||||||||
|
| Tissue inhibitor of metalloproteinases 2 | TIMP2 | P16035 | 282 (35) | 7.45/24.4 (6.7/21.3) | 0.2858 ± 0.105 | 0.1357 ± 0.059 | -2.11 (0.024) | 15 | |
|
| Tissue inhibitor of metalloproteinases 2 | TIMP2 | P16035 | 360 (39) | 7.45/24.4 (7.0/21.3) | 0.7474 ± 0.105 | 0.4013 ± 0.140 | -1.86 (0.002) | 20 | |
|
| Tissue inhibitor of metalloproteinases 1 | TIMP1 | P01033 | 498 (67) | 8.46/23.2 (7.4/23.7) | 0.2818 ± 0.079 | 0.0817 ± 0.033 | -3.45 (0.001) | 18 | |
|
| ||||||||||
|
| Aldose reductase (EC 1.1.1.21) | AKR1B1 | P15121 | 212 (45) | 6.51/35.8 (7.1/34.5) | 0.1718 ± 0.051 | 0.3167 ± 0.050 | 1.84 (0.002) | 28 | |
| * |
|
|
|
|
|
|
|
|
|
|
| * |
|
|
|
|
|
|
|
|
| |
| * |
|
|
|
|
|
|
|
|
| |
| * |
|
|
|
|
|
|
|
|
| |
|
| ||||||||||
|
| Protein-L-isoaspartate O-methyltransferase (EC 2.1.1.77) | PCMT1 | P22061 | 98 (35) | 6.70/24.6 (7.3/22.3) | 0.0238 ± 0.005 | 0.0104 ± 0.002 | -2.29 (0.002) | 12 | |
|
| ||||||||||
|
| Renin receptor precursor (ATPase H(+)-transporting lysosomal accessory protein 2) | ATP6AP2 | O75787 | 104 (380) | 5.76/39.0 (5.6/22.7) | 0.1632 ± 0.064 | 0.0370 ± 0.015 | -4.42 (0.003) | 18 | |
|
| ||||||||||
| * |
|
|
|
|
|
|
|
|
|
|
|
| Plasminogen activator inhibitor 1 precursor | SERPINE1 | P05121 | 88 (23) | 6.68/45.0 (7.9/42.1) | 0.0294 ± 0.010 | 0.0120 ± 0.005 | -2.46 (0.009) | 14 |
All identified proteins have significant MOWSE scores (p < 0.05) of at least 55 and are categorised according to their respective biological functions in the cells.
The expressions of four proteins (marked with * and in bold) were validated by label free LCMS/MS quantification.
Results of in silico analysis using SignalP, SecretomeP and TMHMM servers predicting the localization of identified proteins.
| Spot Number | Protein Name | Swissprot accession number | SignalP | SecretomeP | TMHMM |
|---|---|---|---|---|---|
|
| Cathepsin D(EC 3.4.23.5) | P07339 |
|
| 12.287 |
|
| Cathepsin L1(EC 3.4.22.15) | P07711 |
|
| 2.569 |
|
| Complement C3 precursor | P01024 |
|
| 8.212 |
|
| β-2 microglobulin | P61769 |
|
| 2.525 |
|
| Cystatin-3 | P01034 |
|
| 17.968 |
|
| Glutamate receptor subunit 3A precursor | Q8TCU5 |
|
|
|
|
| Ran-specific GTPase-activating protein | P43487 | 0.102 |
| 0.000 |
|
| GTP-binding nuclear protein Ran | P62826 | 0.115 |
| 0.017 |
|
| Vesicular integral-membrane protein VIP36 precursor | Q12907 |
| 0.222 |
|
|
| Tubulointerstitial nephritis antigen-like precursor | Q9GZM7 |
|
| 1.618 |
|
| Collagen alpha-1(V) chain precursor | P20908 |
| 0.053 | 5.377 |
|
| Cadherin-2 precursor | P19022 |
| 0.203 |
|
|
| Tissue inhibitor of metalloproteinases 2 | P16035 |
|
| 0.246 |
|
| Tissue inhibitor of metalloproteinases 1 | P01033 |
|
| 0.510 |
|
| Aldose reductase(EC 1.1.1.21) | P15121 | 0.184 | 0.395 | 0.001 |
|
| Kexin type 9 precursor(EC 3.4.21.-) | Q8NBP7 |
|
| 16.080 |
|
| Protein-L-isoaspartate O-methyltransferase (EC 2.1.1.77) | P22061 | 0.111 |
| 0.043 |
|
| Renin receptor precursor (ATPase H(+)-transporting lysosomal accessory protein 2) | O75787 |
|
|
|
|
| Moesin | P26038 | 0.111 |
| 0.001 |
|
| Plasminogen activator inhibitor 1 precursor | P05121 |
|
| 2.528 |
a) The presence of signal peptides in a protein sequence was predicted using SignalP 4.0. A protein was classified as being classically secreted when it returned a D-score exceeding 0.450 (indicated by bold numbers).
b)For the prediction of proteins secreted via non-classical secretory pathways, SecretomeP 2.0 was used. Proteins win an N-N score exceeding 0.500 (indicated by bold numbers) were predicted to be secreted.
c)Prediction of transmembrane helixes was performed using TMHMM v2.0. A protein with its expected number of amino acids in transmembrane helixes (ExpAA) exceeding 18.000 (indicated by bold numbers) was predicted to be a plasma protein.
To be classified as “secereted”, a protein must fulfil at least one of the following criteria: It is predicted by SignalP to possess a signal peptide, it is predicted by SecretomeP to non-classically secreted, or, TMHMM predicts that it possesses a transmembrane helix. All proteins, with the exception of aldose reductase (marked with a #), were found to fulfil at least one of these criteria.
Fig 4Secretome networks showing predicted functional linkages between identified proteins.
STRING interaction maps were generated using default settings (Medium confidence of 0.4 and 7 criteria for linkage: neighbourhood, gene fusion, co-occurrence, co-expression, experimental evidences, existing databases and textmining). Twenty additional interplay proteins were also added to each network.
GO enrichment analysis of biological processes involved in the secretome.
| GO Biological process |
|
|---|---|
| Regulation of cellular component organisation | 7.03 x 10−3 |
| Response to cytokine stimulus | 1.11 x 10−2 |
| Regulation of signal transduction | 1.24 x 10−2 |
| ECM organisation | 1.70 x 10−2 |
| Regulation of immune process | 3.53 x 10−2 |
The significance of the GO biological processes was determined by FDR analysis (p< 0.05).
Fig 5Western blot validation of protein expression for RAN.
The position of the RAN protein spot for the secretome of mock control (A) and CHIKV-infected (B) WRL68 cells on 2DE immunoblots. An increase in spot intensity was observed in the CHIKV-infected blot as compared to the mock control blot.
Comparison of real-time qPCR and proteomics results for 15 selected proteins from the secretome sample.
| Gene name | mRNA fold-change ( | Protein fold-change |
|---|---|---|
| ATP6AP2 | NSD | -4.42 |
| B2M | NSD | -1.68 |
| C3 | NSD | -3.21 |
| CDH2 | NSD | -2.97 |
| CST3 | NSD | -2.72 |
| CTSD | NSD | -2.72 |
| CSTL1 | NSD | -2.53, -1.78 |
| COL5A1 | NSD | -3.14 |
| PCMT1 | NSD | -2.29 |
|
|
|
|
| RAN | NSD | 3.68 |
| RANBP | NSD | 1.80 |
| SERPINE1 | NSD | -2.46 |
| TIMP1 | NSD | -3.45 |
| TIMP2 | NSD | -2.11, -1.86 |
RNA expression with similar direction of change to protein expression in 2DE is shown in Bold ( p< 0.05). NSD: no significant differences in the RNA expression.
** More than one protein spot was identified.